CAS: 158580-94-0; 2-Amino-3,4-Difluorobenzoic Acid

相似化合物

170108-07-3 1249285-45-7 1823914-87-9

上下游产品

6,7-difluoro-1H-indole-2,3-dione

6,7-二氟-1H-吲哚-2,3-二酮置于sodium Hydroxide,双氧水体系中,化学反应生成2-氨基-3,4-二氟苯甲酸
参考文献:4-Benzoylisoxazoles And Their Use As Herbicides
标题:4-Benzoylisoxazoles And Their Use As Herbicides
摘要:该发明涉及4-苯甲酰异噁唑化合物,含有它们的组合物,制备过程以及它们作为除草剂的用途.

专利信息

专利号:US-5436368-A
优先权日:1990-10-31
标题:Intermediates in the preparation of 4,5-difluoroanthranillic acid
发明人：BRAISH TAMIM F
权利人:PFIZER
摘要:Compounds of the formula ##STR1## which are intermediates in the preparation of 4,5-difluoroanthranilic acid, an intermediate itself in the synthesis of quinolone antibacterials, and methods of preparing these intermediates.

专利号:CN-101243065-A
优先权日:2005-06-10
标 题:Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related methods of synthesis

专利号:US-2024343719-A1
优先权日:2017-03-17
标题 :Kappa opioid receptor antagonists and products and methods related thereto
发明人：ROBERTS EDWARD; GUERRERO MIGUEL A; URBANO MARIANGELA; ROSEN HUGH; JONES ROBERT M; LAXAMANA CANDACE MAE; ZHAO XIANRUI; TURTLE ERIC DOUGLAS
权利人:SCRIPPS RESEARCH INST; BLACKTHORN THERAPEUTICS INC
摘要:Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: n n n n n n n n n n wherein X, Y, R 1 , R 2 , R 4 , R 5 R 6 , R 7 , R 8 and R 11 are as defined herein.

专利号:US-11897873-B2
优先权日:2017-03-17
标 题:Kappa opioid receptor antagonists and products and methods related thereto
发明人：ROBERTS EDWARD; GUERRERO MIGUEL A; URBANO MARIANGELA; ROSEN HUGH; JONES ROBERT M; LAXAMANA CANDACE MAE; ZHAO XIANRUI; TURTLE ERIC DOUGLAS
权利人:SCRIPPS RESEARCH INST; BLACKTHORN THERAPEUTICS INC
摘要:Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof:wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.